Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma Clinical Trial

— ONTRAC  

Official title:

A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01360853
• Other study ID #: 04-22
• Secondary ID: 11PAN01
• Status: Completed
• Phase: Phase 3
• First received: May 24, 2011
• Last updated: August 2, 2016
• Start date: May 2011
• Est. completion date: December 2015

Study information

• Verified date: August 2016
• Source: Onconova Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The question being asked in this study is: Will patients with advanced pancreatic cancer live significantly longer if they are treated with a combination of Gemcitabine and ON 01910.Na than if they are treated with Gemcitabine alone? There are two parts to this study. In the first part of the study, patients with metastatic pancreatic cancer who have received no prior chemotherapy for this disease will be assigned by chance either to the group that will be treated with both Gemcitabine and ON 01910.Na (about 100 patients will be in this group) or, to the group that will be treated with Gemcitabine only (about 50 patients will be in this group). How long patients survive in the 2 groups will be compared. If it looks like there is no difference between the groups, the study will stop. If it looks like patients in the group that were treated with both Gemcitabine and ON 01910.Na survive longer, the study will continue into a second part where more patients will be treated in order to confirm and better understand the findings of the first part of the study.

Description:

This will be a Phase III study with sample size recalculation after 100 events have occurred. The study will be open-label, randomized, controlled, multi-center and will be conducted at approximately 200 to 300 study sites (60 to 80 study sites in the first portion of the trial).

In the first portion of the study, a total of 150 patients with metastatic pancreatic cancer who have received no prior chemotherapy for this disease will be randomized in a 2:1 fashion to 1 of the 2 following treatment regimens:

• Arm A: Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycle + ON 01910.Na 1800 mg/m2 via 2 hr continuous intravenous infusion (CIV) infusions administered twice weekly for 3 weeks of a 4 week cycle (approximately 100 patients)

• Arm B: Gemcitabine only, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle (approximately 50 patients).

Patients will be stratified at entry using the Eastern Cooperative Oncology Group (ECOG) performance status (ECOG scores of 0 1 vs. ECOG scores of 2; patients with higher scores will not be enrolled).

Patients will remain on study until disease progression or death from any cause, whichever comes first. Moreover, after treatment discontinuation for any cause, all patients will be followed until death.

After 150 patients have been enrolled, accrual will pause and patients will be followed until 100 deaths have occurred. At that time, the Data Safety Monitoring Committee (DSMC) will oversee a formal interim analysis to compare overall survival (OS) between the 2 groups and may recommend early stopping for futility. If the study continues after interim analysis, then the randomization scheme will continue up to 364 patients or the newly-calculated sample size. The maximum number of enrolled patients will be 650. The number of clinical sites may be expanded up to approximately 200 to 300 centers.

Patients in the gemcitabine-only arm (Arm B) will not be allowed to cross over to the combined treatment arm (Arm A). In addition, no palliative radiotherapy will be allowed during the trial.

The primary analysis will compare OS in the ON 01910.Na + gemcitabine arm (Arm A) vs. gemcitabine-only arm (Arm B) once an appropriate number of events has been reached. There are 2 secondary efficacy outcomes: progression-free survival (PFS) and objective response.

Toxicity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03. Grade 3 and 4 hematologic toxicities and > Grade 2 non-hematologic toxicities will be monitored.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 160
• Est. completion date: December 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients at least 18 years old presenting with histopathologically or cytologically confirmed metastatic adenocarcinoma of the pancreas; metastatic disease is defined as disease which has spread beyond the peri-pancreatic lymph nodes.

• Patients must have received no prior chemotherapy for pancreatic cancer, including adjuvant chemotherapy.

• Measurable disease, defined as lesions that can be accurately measured in at least 1 dimension with longest diameter (LD) =20 mm using conventional techniques or =10 mm with spiral computed tomography (CT) scan; measurable lymph nodes must be =15 mm in the short axis.

• ECOG Performance Status of 0, 1, or 2.

• Patients must have adequate renal function and serum creatinine =2.0 mg/dL.

• Patients must have adequate liver function as defined by total bilirubin =2.0 mg/dL and transaminase levels no higher than 3.0 times the institution's upper limit of normal (ULN). Patients with hepatic metastases may have transaminase levels of up to 5.0 times the ULN.

• All patients must have a serum albumin =3.0 g/dL.

• Patients must have adequate bone marrow (BM) function as defined by a granulocyte count =1,500/mm3, a platelet count =100,000/mm3, and hemoglobin >9 g/dL.

• Disease-free period of more than 5 years from prior malignancies other than pancreas (except curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix and ductal carcinoma in situ [DCIS] breast disease).

• Adequate contraceptive regimen (including prescription oral contraceptives [birth control pills], contraceptive injections, intrauterine device [IUD], double-barrier method [spermicidal jelly or foam with condoms or diaphragm], contraceptive patch, or surgical sterilization) before entry and throughout the study for female patients of reproductive potential or female partners of male patients.

• Female patient with reproductive potential must have a negative urine beta human chorionic gonadotropin (bHCG) pregnancy test at Screening.

• Willing to adhere to the prohibitions and restrictions specified in this protocol.

• Patient must have signed an informed consent document.

Exclusion Criteria:

• Patients with unresectable locally advanced disease without evidence of disease elsewhere.

• Life expectancy of less than 12 weeks.

• Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension or seizure disorder.

• Active infection not adequately responding to appropriate therapy.

• Symptomatic or clinically evident ascites.

• Serum sodium less than 130 mEq/L or conditions that may predispose patients to hyponatremia.

• Female patients who are pregnant or lactating.

• Male patients with female sexual partners who are unwilling to follow the strict contraception requirements described in this protocol.

• Major surgery without full recovery or major surgery within 3 weeks of ON 01910.Na treatment start.

• Evidence of brain metastases.

• Any concurrent administration and/or prior administration within 4 weeks of the first dose of study drug, of radiotherapy, or immunotherapy.

• Psychiatric illness/social situations that would limit the patient's ability to tolerate and/or comply with study requirements, or inability to comply with study and/or follow-up procedures (e.g., drug addition, chronic non-compliance, etc.).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adenocarcinoma
• Metastatic Pancreatic Adenocarcinoma
• Pancreatic Neoplasms

Intervention

Drug:
• ON 01910.Na
ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
• Gemcitabine
Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
• Gemcitabine
Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.

Locations

Country	Name	City	State
Hungary	Semmelweis University Department of Diagnostic Radiology and Oncotherapy	Budapest
Hungary	Semmelweis University, 3rd Department of Internal Medicine	Budapest
Hungary	Hetenyi Geza Hospital 5004, Szolnok, Hungary	Szolnok
India	Lifeline Multispeciality Hospitals	Chennai	Tamil Nadu
India	Basavatarakam Indo-American Cancer Hospital	Hyderabad	Andhra Pradesh
India	Jaslok Hospital & Research Centre	Mumbai	Maharashtra
India	Shatabdi Superspeciality Hospital	Nashik	Maharashtra
India	Ruby Hall Clinic	Pune	Maharashtra
India	Regional Cancer Center	Thiruvananthapuram	Kerala
Russian Federation	State Budget Medical Institution of the Arkhangelsk Region	Arkhangelsk
Russian Federation	Chelyabinsk Regional Clinical Oncology Center	Chelyabinsk
Russian Federation	State Budget Medical Institution Clinical Oncology Center 1	Krasnodar
Russian Federation	Budget Medical Institution of the Omsk Region: Clinical Oncology Center	Omsk
Russian Federation	State Budget Medical Institution: Leningrad Regional Clinical Hospital	Saint Petersburg
Russian Federation	State Medical Institution: Tula Regional Oncology Center	Tula
Ukraine	Zakarpattia Regional Clinical Oncology Center Department of Chemotherapy	Uzhhorod
United States	University of Colorado Cancer Center	Aurora	Colorado
United States	Billings Clinic Cancer Center	Billings	Montana
United States	St. Alexis Medical Center-Mid Dakota Clinic PC	Bismarck	North Dakota
United States	Roswell Park Cancer Institute	Buffalo	New York
United States	University of North Carolina Lineberger Comprehensive Cancer Center	Chapel Hill	North Carolina
United States	Medical University of South Carolina - Hollings Cancer Center	Charleston	South Carolina
United States	Levine Cancer Institute	Charlotte	North Carolina
United States	University of Cincinnati Cancer Center	Cincinnati	Ohio
United States	Kaiser Permanente Colorado	Denver	Colorado
United States	Karmanos Cancer Institute	Detroit	Michigan
United States	McLeod Regional Medical Center	Florence	South Carolina
United States	Poudre Valley Cancer Center of the Rockies	Fort Collins	Colorado
United States	Cone Health Cancer Center	Greensboro	North Carolina
United States	Hendersonville Hematology and Oncology at Pardee	Hendersonville	North Carolina
United States	University of Hawaii Cancer Center	Honolulu	Hawaii
United States	UCSD Moores Cancer Center	La Jolla	California
United States	Mount Sinai Comprehensive Cancer Center	Miami Beach	Florida
United States	Vanderbilt-Ingram Cancer Center	Nashville	Tennessee
United States	Yale Cancer Center	New Haven	Connecticut
United States	New York University Langone Medical Center	New York	New York
United States	Desert Comprehensive Cancer Center	Palm Springs	California
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania
United States	Kaiser Permanente NW	Portland	Oregon
United States	Rex Cancer Center UNC Healthcare	Raleigh	North Carolina
United States	University of Rochester Medical Center	Rochester	New York
United States	Pacific Cancer Care	Salinas	California
United States	Premiere Oncology	Santa Monica	California
United States	Seattle Cancer Care Alliance	Seattle	Washington
United States	University of Kansas Cancer Center	Westwood	Kansas
United States	UMASS Medical School	Worcester	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Onconova Therapeutics, Inc.	Academic Oncology Gastrointestinal Cancer Consortium (AGICC)

Countries where clinical trial is conducted

United States,  Hungary,  India,  Russian Federation,  Ukraine, 

References & Publications (5)

Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24. — View Citation

Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower RC. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol. 2008 Dec 1;26(34):5504-10. doi: 10.1200/JCO.2008.17.9788. Epub 2008 Oct 27. — View Citation

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Ber — View Citation

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, F — View Citation

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, F — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival	This study's primary outcome is overall survival, defined as the time from randomization to death from any cause. All patients will be followed until death. Patients lost to follow-up will be censored at the time last known alive.	18 months	No
Secondary	Progression-free survival	Progression-free survival is defined as the time from the randomization to documented disease progression or death. Patients who are alive and do not have disease progression by the clinical cutoff will be censored at the dates of their last tumor evaluation. Kaplan-Meier curves for PFS will be compared using a stratified log-rank test (stratified by ECOG status: 0-1 vs. 2). Hazard ratios and 95% confidence intervals will be estimated using stratified Cox proportional hazards models.	18 months	No
Secondary	Tumor size	Objective tumor response rates using Response Evaluation Criteria In Solid Tumors (RECIST).	18 months	No
Secondary	Safety/tolerability	Toxicity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03	18 months	Yes
Secondary	QOL questionnaire	Quality of life (QOL) questionnaire, using the European Organisation for Research and Treatment of Cancer(EORTC) QLQ-C30 version 3.	18 months	No
Secondary	Biomarkers	In this study, archival tissue will be collected and analyzed in order to identify molecular characteristics of pancreas tumors, which may confer susceptibility or resistance to gemcitabine alone or in combination with ON 01910.Na.	18 months	No
Secondary	Population Pharmacokinetics	Measurement of ON 01910.Na in plasma of all patients in Arm A 1 hour after starting ON 01910.Na infusion at Day 1 and Day 15 in Cycle 1 only.	18 months	No
Secondary	Full Pharmacokinetics	At a limited number of sites, blood samples for measurement of ON 01910.Na and gemcitabine will be obtained at Cycle 1 Day 1 only, in a subset of 10 patients in Arm A, at the following 12 time-points: predose; 15 min after starting gemcitabine infusion; 30 min, immediately before ending gemcitabine infusion; 15 min after starting ON 01910.Na infusion; 30 min after ON 01910.Na infusion start; immediately before ending ON 01910.Na infusion; and, 15 min, 30 min, 1 hr, 2 hr, 4 hr and 8 hr after ending ON 01910.Na infusion.	18 Months	No

External Links

•   Related information about Academic Oncology Gastrointestinal Cancer Consortium (AGICC).
•   Related information about Onconova Therapeutics, Inc.